Seer, Inc. (NASDAQ: SEER) is a Healthcare company (Biotechnology) with a market capitalization of $81M. The Maz Rating grades it against the other companies in its sector.
Seer, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.46, Seer, Inc. trades at 5.9x sales and 0.4x book value. Over the last twelve months it generated about $14M of revenue and a net loss of $64M. It runs a gross margin of 45.7%, an operating margin of -477.2% and a net margin of -457.9%. It shows return on equity of -27.0%, return on invested capital of -28.2% and a free cash flow yield of -56.9%. On the balance sheet: a debt-to-equity ratio of 0.10 and a current ratio of 16.89. Over the past 52 weeks the share price ranged from $1.42 to $2.38, with a beta of 1.45.
Seer, Inc. does not currently pay a dividend.
4 Wall Street analyst ratings cover the stock: 1 Buy, 2 Hold and 1 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Seer, Inc. (SEER) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 186.2% / 30% · Interest income / Revenue 49.3% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 145.8% / 33% · Receivables / Mkt Cap (36m) 3.58% / 49% · Interest income / Revenue 49.3% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 145.8% / 33.33% · Receivables / Mkt Cap (24m) 3.58% / 33.33% · Interest income / Revenue 49.3% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 3.89% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 62.0% / 33.33% · Receivables / Avg Assets (4Q) 1.64% / 33.33% · Interest income / Revenue 49.3% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 64.5% / 33.33% · (Cash+Recv) / Total Assets 66.1% / 33.33% · Interest income / Revenue 49.3% / 5% | Fail |
No. As of September 2026, Seer, Inc. (SEER) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Seer, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 49.3% of each dividend: Seer, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.